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Objective. To study self-reported pain early in the disease course of juvenile idiopathic 
arthritis (JIA) as predictor of long-term disease outcomes. 
Methods. Consecutive cases of JIA with disease onset 1997-2000 from defined geographical 
areas of Norway, Sweden, Finland and Denmark were prospectively enrolled in this 
population-based cohort study. Self-reported, disease-related pain was measured on a 10 cm 
visual analogue scale (VAS pain). Inclusion criteria were a baseline visit with pain score six 
months after disease onset, followed by an eight-year study visit. Remission was defined 
according to Wallace preliminary criteria. Functional disability was measured by Childhood 
Health Assessment Questionnaire (CHAQ) and Child Health Questionnaire (CHQ-PF50) if age 
<18 and Health Assessment Questionnaire (HAQ) if age ≥18 years. Damage was scored using 
the Juvenile Arthritis Damage Index (JADI). 
Results. The final study cohort consisted of 243 participants, and 120 (49%) had oligoarticular 
onset. At baseline 76% reported VAS pain >0 compared to 57% at eight-year. Half of those 
who reported baseline pain also reported pain at eight-year, but at a lower intensity. Compared 
to no pain, higher pain intensity at baseline predicted more pain at eight-year, more functional 
disability, more damage and less remission off medication. Baseline pain predicted more use of 
DMARDs/biologics during the disease course. Participants with oligoarticular JIA reporting 
pain at baseline were more likely to develop extended oligoarticular or other unfavorable JIA 
categories. 
Conclusion. Early self-reported, disease-related pain among children and adolescents with JIA 
is common and seems to predict persistent pain and unfavorable long-term disease outcomes.
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SIGNIFICANCE AND INNOVATIONS  
 
Pain is a frequent complaint, tends to persist, and affects health-related quality of life for 
children and adolescents with juvenile idiopathic arthritis (JIA). 
 
In this study, we show for the first time that early pain report is associated to long-term non-
remission, functional impairment, more use of DMARDs/biologics, and for those with 
oligoarticular JIA, development into extended disease. 
 
The study adds to the increasing amount of evidence establishing the importance of pain 





























Juvenile idiopathic arthritis (JIA) is a diverse chronic disease with onset before 16 years of age. 
This most common rheumatic disease among children is characterized by at least six weeks of 
continuous arthritis in one or more joints of unknown cause (1). The incidence rate in the 
Nordic countries is reported to be about 15-22/100.000 children (2-4). JIA is a heterogeneous 
disorder classified into seven categories based on defined criteria occurring during the first six 
months after disease onset (5). Among the different categories, and within each category, the 
disease course and outcome differ markedly (6). Persistent oligoarticular JIA has the best 
prognosis of all JIA categories (7). Extended oligoarticular JIA has a more unfavorable 
outcome, similar to polyarticular disease (8, 9). Predicting outcome is challenging, and several 
studies have focused on associations between long-term outcome and clinical characteristics 
and biomarkers, such as the nature of joint involvement, the intensity of acute-phase response 
and the existence of autoantibodies and genetic variables (10). As none of those predictors are 
perfect, and in order to tailor treatment to reach the target of clinical remission, there is a need 
for more prospective longitudinal studies to evaluate early predictors using validated and 
multidimensional measures (10). More patient-centered measurements have been demanded 
for assessment of the course and outcome of JIA (11). Among the six core variables endorsed 
by the American College of Rheumatology (ACR) (12), only the parent/patient assessment of 
overall well-being can be defined as a patient-reported measure. Patients, parents and clinicians 
have pointed to more specific quality of life measures, and especially pain, as important 
measures when evaluating the course and outcome of JIA (11). 
 
Pain is a frequent complaint among children and adolescents with JIA (13, 14). Pain perception 
is highly subjective and different self-reported measures are used to detect pain frequency and 
intensity (15, 16). Pain assessment in young children is especially challenging because pain 
 5 
reports are dependent on the parents´ assumption of their child´s pain (17). There are both 
unidimensional and multidimensional tools available for parent and child/adolescent 
assessment of pain in JIA (16). Among the unidimensional tools, the visual analogue scale 
(VAS) is a commonly used and validated scoring instrument (18, 19). The pathogenesis of pain 
in children and adolescents with JIA is multifactorial, including both biological and 
psychosocial factors (16, 20). Pain is a distressing symptom, and several studies have 
elucidated the relationship between pain, functional disability and health-related quality of life 
(21-24), but information about pain, as a predictor of long-term disease outcome is lacking. 
 
In our Nordic population-based JIA cohort with comprehensive and prospectively sampled 
data, we have previously studied different aspects of JIA (2, 8). In this project, we aimed to 




PATIENTS AND METHODS 
 
Patients. The Nordic JIA cohort is a population-based cohort study. Consecutive cases of 
newly diagnosed JIA from defined geographical areas of Norway, Sweden, Finland and 
Denmark with disease onset from January 1, 1997, to June 30, 2000, were prospectively 
included. Disease onset was defined as the day the child fulfilled the criteria for active arthritis 
according to information given by the parents/patient or by a physician.  Participants were 
included consecutively and as soon as possible after the diagnosis was determined. However, 
the first extensive baseline visit was scheduled to six months after disease onset. This time 
point was chosen to enable classification of the disease into a JIA category, according to the 
International League Against Rheumatism (ILAR) Edmonton criteria (5). We have no 
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registration of onset symptoms in the database. Detailed description of data collection and 
patient enrollment has previously been published (2, 8). In the present study participants were 
included if they had at least a baseline visit six months after disease onset with available pain 
scores, and participation in the eight-year follow-up visit. At both visits, we had data from 
clinical examinations, disease activity measures, previous and ongoing medication, damage 
and remission status, as well as results from blood tests. Health-related quality of life was 
reported by the children or by their parents.  
 
Measures. Self-reported, disease-related pain intensity during the previous week was 
measured on a 10 cm visual analogue scale (VAS pain) (0 = no pain and 10 = worst possible 
pain) by the children if age ≥9 years or by the parents if younger. VAS pain was assessed with 
the question; “How do you rate your/your child´s pain due to your/his or her illness in the past 
week?” As in previous studies on pain in JIA, pain analyses were explored both by 
categorization of VAS pain into =0, >0-3, >3-7 and >7-10, and dichotomized into =0 (no pain) 
or >0 (15, 24-26). We performed sub-analyses on VAS pain scores in participants <9 years and 
≥9 years to look for any discrepancies between parent- and patient-reported pain (27). Self-
reported physical disability questionnaires were the disease-specific and validated Childhood 
Health Assessment Questionnaire (CHAQ) (0 = no difficulty and 3 = unable to do) if age <18 
years (28, 29), and the Health Assessment Questionnaire (HAQ) (0 = no difficulty and 3 = 
unable to do) if age ≥18 years (30). Children ≥9 years filled in the CHAQ and for those <9 
years, parents filled in. For children <18 years, the parent form of the generic health-related 
quality of life instrument, the Child Health Questionnaire (CHQ-PF50), was answered by the 
parents, yielding a physical summary score (PhS) and a psychosocial summary score (PsS) (0-
100, 0 = worst, mean 50, SD ±10) (28, 31, 32). This instrument is designed to capture the 
child´s physical and psychosocial well-being independent of his/her disease and it is 
comparable to norm scores from the general U.S. population. For the remainder of the paper 
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CHQ refers to CHQ-PF50. Damage was scored by experienced pediatric rheumatologists using 
the Juvenile Arthritis Damage Index (JADI) assessment of articular damage (JADI-A) (scale 
0–72, 0 = no damage) and extraarticular damage (JADI-E) (scale 0-17, 0 = no damage) (8, 32). 
Damage was defined as either JADI-A and/or JADI-E >0. As in previous studies, CHAQ/HAQ 
and JADI were dichotomized into 0 (no disability, no damage) or >0 (8, 24, 33). Physical and 
psychosocial summary scores of CHQ were dichotomized into <40 (poor health) or ≥40 (better 
health) (28, 31). Remission was defined according to the preliminary criteria described by 
Wallace et al. (34). Remission status was dichotomized into Remission off medication or Not 
in remission off medication (33). The latter included; Active disease, Inactive disease not yet in 
remission and in Remission on medication.  
 
Ethical issues. Medical research ethical committees from each participating country gave their 
approval according to national practice and regulations in accordance with the Declaration of 
Helsinki. Written informed consent was obtained from children ≥16 years and if aged <16 
years, from their parents. 
 
Statistical analysis. We used descriptive statistics with median and interquartile ranges (IQR) 
for continuous variables, and absolute frequency, percentage with 95% confidence interval (CI) 
for categorical variables. To evaluate the predictive value of pain at baseline for outcome 
measures after eight years and medication during the disease course, model-based absolute 
risks were estimated after binominal regression using the post-estimation command lincom in 
STATA. Sex adjustment was weighted 0.7 for girls to mimic the distribution in the population. 
In additional analyses, we also adjusted for age. To estimate absolute risks, we used the mean 
age at onset of 6.8 years. We used logistic regression to estimate odds ratio (OR) with 95% CI 
using VAS pain as a continuous variable. In further analyses, we made receiver operator 
characteristic (ROC) curves based on measures of sensitivity and specificity. The area under 
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the curve (AUC) was calculated with 95% CI, and with the following interpretations; an area 
of 0.5 or lower were considered as no discrimination, ≥0.7 to <0.8 as acceptable 
discrimination, ≥0.8 to <0.9 as excellent discrimination, ≥0.9 as outstanding discrimination 
(35). Statistical analyses were carried out using STATA version 14, software (STATA Corp., 





Clinical characteristics of the study group  
Of the 500 patients included from the four Nordic countries, 440 participated in the eight-year 
follow-up. Due to lack of baseline pain scores, all Finnish participants (n =138) and additional 
59 participants from the other countries were excluded. The final study population consisted of 
243 children (Figure 1) with a median baseline visit of seven and a final follow-up visit of 97 
months (Table 1). Among these, 70% were female, 49% had oligoarticular disease, median age 
was 6.3 years at onset and 14.9 years at follow-up (Table 1). The diagnostic delay was short, 
median interval between disease onset and diagnosis of arthritis by a physician was 50.5 days, 
interquartile range (IQR) 14-101 days. Of these 243 participants, intraarticular corticosteroid 
injections had been given to 91, and for 34 of these within the last three months of the baseline 
visit (results not shown).  At this baseline visit, none of the participants used biologics, but 20 
used systemic steroids. Methotrexate was used by 31 of the participants, and of those 8 had 
cumulative doses ≥100 mg. The 60 participants that did not participate in the eight-year study 
did not differ significantly in the proportion of oligoarticular JIA or with respect to sex, and 
had a median follow-up of 47 months (range 5-83 months). At their last registered visit, 30 
(50%) had a pain assessment, including 21 with VAS pain >0 and nine with VAS pain =0. 
Participants excluded from the present study due to lack of pain data at baseline had lower 
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median age (5.1 versus 6.3 years) and the proportion of boys was slightly higher (39% versus 
30%). There was no difference in the proportion of oligoarticular JIA at onset and remission 
status at eight years between the included and excluded participants. 
 
Pain scores 
More participants reported VAS pain >0 at the baseline visit (76%) than at eight years (57%). 
The mean pain intensity score (VAS pain) of those reporting pain were higher at baseline, 3.0 
(95% CI 2.6-3.3) than at eight years, 2.4 (95% CI 2.0-2.8). The distribution of pain intensity 
scores at the baseline visit and at the eight-year follow-up is shown in Supplementary Figure 1. 
For participants <9 years at baseline, 118 of 159 (74%) had a parent-reported pain score >0 
with a mean intensity of 2.7 (95% CI 2.3-3.0), while 67 of 84 (79%) participants ≥9 years had 
a patient-reported pain score >0, mean intensity of 3.5 (95% CI 2.9-4.1). Among participants 
with pain measures both at baseline and eight years (n =204), 50% reported VAS pain >0 at 
both visits, and 19% reported no pain at both visits (Figure 2). We divided this group into 
participants <9 and ≥9 years at baseline. Participants <9 years had parent-reported pain scores 
at their first visit and patient-reported pain scores at their last visit, and 48% reported VAS pain 
>0 at both visits. Participants ≥9 years had only patient-reported pain scores, and 55% reported 
VAS pain >0 at both visits (results not shown).  
 
Baseline pain scores and long-term outcome measures 
The association between baseline pain scores subdivided into four categories of pain intensity, 
and long-term outcome measures are shown in Table 2. Participants reporting VAS pain >0 at 
the baseline visit, more frequently reported pain and functional disability (CHAQ/HAQ >0) at 
the eight-year follow-up. A distinct dose-response was observed with increasing pain intensity 
at baseline. Using VAS pain as a continuous variable, we observed increased odds ratio for the 
different long-term outcomes. Functional disability as presented by CHQ PhS, demonstrated 
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similar results. Participants reporting pain at baseline, more frequently were not in remission 
off medication at follow-up, compared to those reporting no baseline pain. A similar 
association between increasing pain intensity at baseline and long-term remission status was 
observed, but the dose-response relationship tended to level out at the most extreme pain 
intensities. Participants reporting no pain at baseline, rarely reported pain (28%) and functional 
disability (18%) at eight years, and 74% were in remission off medication. In all analyses, we 
adjusted for sex, and additional adjustment for age did not change the results. Similar to the 
results on long-term remission, pain and functional disability, baseline pain was associated 
with the use of DMARDs and biologics during the eight-year disease course (Supplementary 
Table 1). In contrast to the other eight-year outcome measures, psychosocial health assessed 
with CHQ PsS, did not show association to baseline pain score (results not shown). The 
predictive ability of baseline pain was also analyzed using receiver operator characteristic 
(ROC) curves, giving acceptable discrimination between early pain scores and long-term 
outcomes of pain, functional disability and not being in remission at eight years, but no clear 
discrimination was observed for long-term damage (Figure 3).  
 
Baseline pain scores and long-term outcomes in the oligoarticular category 
Among participants with oligoarticular JIA reporting VAS pain >0 at the baseline visit, 48% 
(95% CI 38-60%) developed extended oligoarticular disease or other JIA categories during the 
course of the disease compared to 30% (95% CI 16-44%) of those reporting no pain (Table 3). 
Also, a higher proportion of participants with VAS pain >0 at baseline, was not in remission 
off medication, 65% (95% CI 55-76%), and reported pain, 61% (95% CI 50-73%) at eight 
years, compared to those reporting no pain at baseline. In contrast, 70% (95% CI 56-84%) of 
those reporting no pain at baseline remained in the persistent oligoarticular JIA category at the 
eight-year follow-up. The associations were strengthened using VAS pain as a continuous 
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Among participants in the population-based Nordic JIA study, a higher proportion reported 
disease-specific pain seven months after disease onset, and the pain was of higher intensity 
compared to the eight-year follow-up. Half of the participants reporting pain at baseline also 
reported pain at eight years. Self-reported pain early in the disease course predicted more pain, 
more functional disability, more damage, more use of DMARDs/biologics, and more long-term 
disease activity at eight years. In addition, participants with oligoarticular JIA and VAS pain 
>0 at baseline, more often developed an extended disease or other unfavorable JIA categories.  
 
The strength of our study is the longitudinal and population-based design, a robust 
international cohort, and the use of validated and multidimensional outcome measures. The 
novelty in looking at associations between early pain report and long-term remission status, 
medication, and development into more unfavorable disease categories, is also a major 
strength. Some limitations must be recognized. The exclusion of all the Finnish participants 
reduced the number of study participants, but did not change the population-based design of 
the study. The missing early pain scores from the other countries might have skewed the 
remaining cohort, but the distribution of JIA categories and the remission status were 
comparable among those with or without early pain scores. Even though the VAS pain 
instrument is disease-specific, we cannot rule out that other musculoskeletal co-conditions, 
such as generalized joint hypermobility, specific onset symptoms or differences in timing of 
diagnosis, might have influenced the child´s/parent´s pain rating. However, this is a challenge 
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to all pain research. Since pain is a subjective descriptor, our cohort is close to population-
based, and trained pediatric rheumatologists ascertained the JIA diagnosis, we do not think that 
this will seriously disturb the interpretation of our results. Similarly, we cannot ascertain the 
nature of “bodily pain” the participants scored when filling out this question in the CHQ 
questionnaire. However, we only used this question in accordance with the CHQ instructions, 
as one of many items describing a summary of physical function, and not as a pain measure. 
Parents reporting their child´s pain for children <9 years constituted a majority of pain reports 
at the baseline visit, but a small minority at the eight-year follow-up. We cannot rule out some 
element of parent/child discordance, although the sub-analyses on pain-reports according to 
age at baseline seem to indicate that this was not a major problem. This is in accordance with a 
study from 2006, showing moderate agreement between parent´s and child´s pain rating (17). 
Our results are not directly comparable, because the parent/child pain reports are not from the 
same visit. The early pain scores from the baseline study visit seven months after disease onset, 
were given by participants both off and on medication, but only few had started disease-
modifying anti-rheumatic drugs (DMARDs). 
 
Consistent with previous research, we found pain as a frequent complaint among the 
participants in our study cohort (14, 16, 36). We found a reduction in number of participants 
reporting pain from baseline (76%) to the eight-year follow-up (57%). A quite similar 
reduction was found by Lovell et al in 1989 demonstrating pain frequency of 60% at baseline, 
50% at one-year follow-up and 40% at five-year follow-up (37). In a recent 30-year follow-up 
study of JIA in Norway, 66% of the participants reported pain of some degree (24). 
 
In accordance with other studies, the intensity of pain was mainly in the mild to moderate 
range (19, 37, 38). Our results on early pain intensity with mean VAS pain 3.0 are consistent 
with a recent cross-sectional study in children and adolescents with JIA from southeastern 
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region of the United States, showing mean VAS pain of 2.6 (13). Our results on pain intensity 
at the eight-year follow-up appear to be lower compared to other studies (14, 39). These studies 
are, however, skewed to the severe end of the spectrum of JIA, whereas our population-based 
study included the full disease spectrum. Also, to compare studies on pain, age and disease 
duration must be taken into account.   
 
Even in the biologic era with generally good disease control, persistent pain during the course 
of the disease remains a concern (26, 40, 41). Half of our participants reporting pain seven 
months after disease onset also reported pain at the eight-year follow-up, indicating high pain 
persistency. This is in agreement with other studies showing that a significant number of 
children and adolescents with JIA continue to report pain during the course of disease and into 
adulthood (14, 24, 42). It is of notice that the proportion of pain persistence is fairly similar 
whether the parents report their child´s pain, or the pain was self-reported at baseline. Pain 
persistence despite seemingly good treatment response, supports theories that the causes of 
pain are multifactorial (41, 43). Both psychosocial and biologic factors contribute to these 
children´s subjective experience of pain (38, 44, 45).  
 
Pain as a predictor of unfavorable health-related quality of life in children with JIA is widely 
studied (21, 23, 46, 47). In a multinational quality of life study from the Pediatric 
Rheumatology International Trials Organization (PRINTO), pain was found to be a predictor 
of psychosocial well-being (21). In agreement with our study, previous studies have concluded 
that pain at presentation was a strong predictor of persistent pain (42, 48). In accordance with 
our results, pain as a predictor of functional disability was also found in a small cross-sectional 
study from the United States (49). Except for health-related quality of life outcomes and 
functional disability, studies that specifically address pain as predictor of other long-term 
outcomes, such as remission, damage, medication, and changing of JIA categories, are lacking. 
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Our results demonstrate for the first time, that early pain is associated with not achieving 
remission off medication in a long-term perspective. We also demonstrate, for the first time, 
that early pain reports predict a higher risk of development into extended oligoarticular or other 
unfavorable JIA categories during the course of the disease. This suggests that early pain may 
be an indicator of subclinical disease activity or a marker of a more severe disease category. 
This is also supported by the fact that a higher proportion of participants with early pain report 
used DMARDs/biologics during the course of the disease. 
 
Even though pain assessment has been highlighted as a quality measure of pediatric arthritis 
care (50), pain scores are infrequently used as guiding tools in daily care of these patients (41). 
Our results demonstrate that pain complaints in children with JIA at an early stage in their 
disease should be taken seriously, not just to relieve ongoing discomfort, but probably also as a 
sign of ongoing clinical or subclinical disease activity. This emphasizes the importance of pain 
assessment in routine care of children and adolescents with JIA. In a Canadian study where 
patients, parents and clinicians were asked what matters most in the care of JIA, pain was one 
of the five most important factors (11). The active joint count was the only one of these five 
factors that is included in the pediatric version of the American College of Rheumatology 
(ACR) core variables for clinical care in children with JIA (12). The association between early 
pain reports and long-term unfavorable outcome adds to the discussion on the validity of the 
ACR core variables, and whether pain should be included in these variables. 
 
In conclusion, early self-reported pain in JIA is common, tends to persist, and seems to predict 
unfavorable long-term disease outcome in several outcome dimensions.  
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 n (%) 
Female sex 243  170 (70) 
Oligoarticular JIA at onset 243  120 (49) 
Median age at disease onset, years 243 6.3 (2.9-10.3)a   
Median age at the 8-year follow-up, years 243 14.9 (11.1-18.5)a   
Disease duration at the baseline visit, months 243 7 (6-9)a   
Disease duration at the 8-year follow-up, months 243 97 (95-102)a   
VAS pain
b>0 at the baseline visit 243  185 (76) 
VAS pain
b >0 at the 8-year follow-up 204  117 (57) 
CHAQ/HAQ >0 at the 8-year follow-up 207  80 (39) 
CHQ PhS <40 at the 8-year follow-up 132  25 (19) 
CHQ PsS <40 at the 8-year follow-up 132  7 (5) 
JADI >0 at the 8-year follow-up 203  46 (23) 
Not in remissionc at the 8-year follow-up 236  135 (57) 
CHAQ = Childhood Health Assessment Questionnaire, age <18 years; HAQ = Health 
Assessment Questionnaire, age ≥18 years; CHQ PhS = Child Health Questionnaire physical 
summary score (0-100); CHQ PsS = Child Health Questionnaire psychosocial summary score 
(0-100); JADI = Juvenile Arthritis Damage Index assessment of articular damage (JADI-A) 
and extraarticular damage (JADI-E) 
aInterquartile range  
bSelf-reported pain was measured on a 10 cm visual analogue scale (VAS pain) 




Table 2.  Association between baseline pain report and long-term outcomes in juvenile idiopathic arthritis (JIA) 
Pain scores seven months 
after disease onset 











VAS paina =0 
n/total 











      
VAS paina >0-3 
n/total  











      
VAS paina >3-7 
n/total  











      
VAS paina >7-10 
n/total  











      
VAS paina continuousd 
OR (95% CI)c 1.5 (1.2-1.7) 1.4 (1.2-1.6) 1.4 (1.1-1.7) 1.1 (0.9-1.2) 1.2 (1.1-1.4) 
CHAQ = Childhood Health Assessment Questionnaire, age <18 years; HAQ = Health Assessment 
Questionnaire, age ≥18 years; CHQ PhS = Child Health Questionnaire physical summary score (0-100); JADI = 
Juvenile Arthritis Damage Index assessment of articular damage (JADI-A) and extraarticular damage (JADI-E); 
OR = Odds ratio; CI = Confidence interval 
aSelf-reported pain was measured on a 10 cm visual analogue scale (VAS pain) 
bNot in remission off medication according to the definition by Wallace et al. (34) 
cAdjusted for sex, weighted 0.7 for girls 




Table 3.  Association between baseline pain report and long-term outcomes in juvenile idiopathic arthritis (JIA) 
with oligoarticular onset 
 
Pain scores seven  
months after  
disease onset   
Clinical characteristics at the eight-year follow-up 
Extend. 
Oligo./othersa 








VAS paind =0 
n/total  











      
VAS paind >0  
n/total  











      
VAS paind continuousg  
OR (95% CI)f 
 
1.3 (1.1-1.6) 1.4 (1.1-1.8) 1.4 (1.1-1.8) 1.0 (0.8-1.3) 1.3 (1.0-1.5) 
Extend. Oligo. = Extended oligoarticular JIA; CHAQ = Childhood Health Assessment Questionnaire, age <18 
years; HAQ = Health Assessment Questionnaire, age ≥18 years; JADI global = Juvenile Arthritis Damage Index 
assessment of articular damage (JADI-A) and extraarticular damage (JADI-E); Not in remission = Not in 
remission off medication; OR = Odds ratio; CI = Confidence interval 
aOligoarticular JIA at six months changed to either extended oligoarticular or other JIA categories at the eight-
year follow-up 
bOthers were one with enthesitis-associated arthritis and two with undifferentiated arthritis 
cOthers were two with psoriatic arthritis, six with enthesitis-associated arthritis and two with undifferentiated 
arthritis 
dSelf-reported pain was measured on a 10 cm visual analogue scale (VAS pain) 
eAccording to the definition by Wallace et al. (34) 
fAdjusted for sex, weighted 0.7 for girls 





















8-year follow-up with 









Missing at 8-year  
follow-up 
n =60 
Finnish participants did 
not fill in the pain score 
7 months after  
disease onset 
n =138 
Pain score missing  

















                     
 
 
VAS pain >0  
at 7 months  
n =150 
VAS pain =0 
both at  
7 months and  
8 years  
n =39 
 
VAS pain >0 



















Supplementary Table 1.  Association between baseline pain report and medication during the eight-year disease 
course in juvenile idiopathic arthritis (JIA) 
Pain scores seven 
months after  
disease onset 
Medication during the disease course 
 
Medication at the eight-year follow-up visit 
Methotrexate Biologics 
DMARDs/ 
Biologics  Methotrexate Biologics 
DMARDs/ 
Biologics 
VAS paina =0 
n/total 













VAS paina >0 
n/total 













VAS paina continuousc 
OR (95% CI)b 1.3 (1.2-1.5) 1.2 (1.1-1.4) 1.5 (1.3-1.7)  1.1 (1.0-1.3) 1.2 (1.0-1.4) 1.2 (1.1-1.4) 
Methotrexate = Methotrexate oral/parenteral; Biologics = Etanercept, infliximab or adalimumab; DMARDs = Disease-
modifying anti-rheumatic drugs including methotrexate, hydroxychloroquine, cyclosporine, sulfasalazine, intravenous 
immunoglobulin, leflunomide, azathioprine, gold, and mycophenolate mofetil. Patients may have received more than 
one of these medications during the disease course; OR = Odds ratio; CI = Confidence interval 
aSelf-reported pain was measured on a 10 cm visual analogue scale (VAS pain) 
bAdjusted for sex, weighted 0.7 for girls 













Figure 1. Flow-chart of the study population. F = female. M = male. 
 
Figure 2. Venn diagram demonstrating pain persistency in the Nordic JIA study cohort. The 
cohort included 204 participants with pain measures seven months after disease onset and at 
the eight-year follow-up. Disease-related pain was measured on a 10 cm visual analogue scale 
(VAS pain) (0 = no pain and 10 = worst possible pain). Continuous circle represents VAS pain 
>0 at seven months and dashed circle represents VAS pain >0 at eight years.  
 
Figure 3. Receiver operator characteristic (ROC) curves in the Nordic JIA study cohort for 
different disease outcomes after eight years compared to self-reported disease-related pain 
(VAS pain) at seven months. Pain was measured on a 10 cm visual analogue scale (VAS pain) 
(0 = no pain and 10 = worst possible pain). Remission was defined according to the 
preliminary criteria described by Wallace et al. (34). Functional disability was measured with 
Childhood Health Assessment Questionnaire/ Health Assessment Questionnaire 
(CHAQ/HAQ). Damage was measured with the Juvenile Arthritis Damage Index (JADI), 
articular and extraarticular. The area under the curve (AUC) values were 0.74 (95% CI 0.67-
0.80) for persistent pain, 0.68 (95% CI 0.61-0.75) for not being in remission, 0.71 (95% CI 
0.64-0.79) for functional disability and 0.58 (95% CI 0.50-0.67) for joint damage. 
 
Supplementary Figure 1 
Distribution of participants in the Nordic JIA study cohort with self-reported disease-related 
pain scores >0. A; at seven months after disease onset (n =185/243), and B; at the eight-year 
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follow-up (n =117/204). Pain was measured on a 10 cm visual analogue scale (VAS pain) (0 = 
no pain and 10 = worst possible pain). 
